Macter International reports FY26 revenue of PKR 11.73bn, highlighting strong operational growth and R&D focus.
Macter International Limited
Corporate Briefing Session • FY 2025-26
Macter International Limited (MACTER) presented its Corporate Briefing Session for FY 2025-26, highlighting robust financial growth, strategic investments in biotechnology, and expansion into new global markets.
Key Highlights
- Financial Growth: Net revenue for FY2025-26 stood at PKR 11.73 billion, with a 5-year revenue CAGR of 22%.
- Operational Efficiency: Gross margins saw a 27% increase driven by an improved sales mix and expanded export volumes.
- Strategic Investment: Committed PKR 154 million to R&D in FY26 to foster innovation in complex formulations.
- Product Portfolio: Successful launch of advanced therapies, including r-DNA biological Semaglutide and Tirzepatide.
- Market Reach: Strengthened domestic distribution with over 900 medical representatives covering 20,000+ doctors.
Key Financials (FY2025-26)
Net Revenue
PKR 11.73 Bn Profit Before Tax
PKR 1.25 Bn Export Sales Growth
147% (excl. Afghanistan) Opportunities & Outlook
- Expansion: Targeting new commercial markets including Kazakhstan, Cameroon, and Burkina Faso.
- Manufacturing: Pioneer in Pakistan for the lyophilization of rDNA/Biologics, with high-tech capacity for difficult-to-make dosages.
- Efficiency: Focus on cost optimization and efficiency enhancements to sustain bottom-line growth.
Investor Takeaway: Macter continues to demonstrate strong growth through a focus on niche segments and high-value biotech products. The significant export growth and sustained R&D investment present a positive long-term outlook.